Hoylaerts M F, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
Biochem J. 1995 Mar 1;306 ( Pt 2)(Pt 2):453-63. doi: 10.1042/bj3060453.
In the absence of high shear forces, the in vitro binding of human von Willebrand factor (vWF) to its platelet receptor glycoprotein Ib (GPIb) can be promoted by two well-characterized mediators, botrocetin and ristocetin. Using purified vWF and GPIb, we have investigated the mechanisms by which ristocetin mediates this binding. Specific binding of vWF monomers to GPIb occurred with a 1:1 stoichiometry, but high-affinity binding required the participation of two ristocetin dimers. Binding was strongly dependent on pH and inhibited by low poly-L-lysine concentrations, indicating ristocetin-dependent charge neutralization during the interaction. With increasing ristocetin concentrations, vWF binding depended progressively less on the involvement of its A1 loop, which is compatible with a model in which the two ristocetin dimers bridge the vWF-GPIb complex on secondary sites. In agreement with this model, the ristocetin-dimer-promoted stabilization of vWF on GPIb was abolished by low concentrations of poly(Pro-Gly-Pro), which is known to complex ristocetin dimers. Mechanistic analysis of the inhibition of vWF binding by the recombinant vWF fragment Leu504-Ser728 (VCL), which covers the entire A1 loop, revealed an affinity of VCL for GPIb comparable with that of the botrocetin-vWF complex for GPIb, and identified a specific but 20-fold lower affinity of VCL in the presence of ristocetin. The proline-rich peptides flanking the vWF A1 loop, Cys474-Val489 and Leu694-Asp709, inhibited vWF binding semispecifically by competitively interfering with the formation of the GPIb-vWF complex rather than by complexation of free ristocetin dimers. In conclusion, ristocetin-promoted binding of vWF to its GPIb receptor results from charge neutralization and interactions involving proline residues in the vicinity of the natural interaction sites present on both GPIb and the A1 domain of vWF.
在没有高剪切力的情况下,人血管性血友病因子(vWF)与其血小板受体糖蛋白Ib(GPIb)的体外结合可由两种特征明确的介质促进,即蛇毒巴曲酶和瑞斯托霉素。我们使用纯化的vWF和GPIb,研究了瑞斯托霉素介导这种结合的机制。vWF单体与GPIb的特异性结合以1:1的化学计量比发生,但高亲和力结合需要两个瑞斯托霉素二聚体的参与。结合强烈依赖于pH值,并受到低浓度聚-L-赖氨酸的抑制,这表明在相互作用过程中存在瑞斯托霉素依赖性电荷中和。随着瑞斯托霉素浓度的增加,vWF结合对其A1环参与的依赖性逐渐降低,这与一种模型相符,即两个瑞斯托霉素二聚体在二级位点桥接vWF-GPIb复合物。与该模型一致,低浓度的聚(脯氨酸-甘氨酸-脯氨酸)可消除瑞斯托霉素二聚体促进的vWF在GPIb上的稳定作用,已知聚(脯氨酸-甘氨酸-脯氨酸)可与瑞斯托霉素二聚体形成复合物。对覆盖整个A1环的重组vWF片段Leu504-Ser728(VCL)抑制vWF结合的机制分析表明,VCL对GPIb的亲和力与蛇毒巴曲酶-vWF复合物对GPIb的亲和力相当,并确定在存在瑞斯托霉素的情况下VCL的亲和力特异性降低了20倍。vWF A1环两侧富含脯氨酸的肽段Cys474-Val489和Leu694-Asp709通过竞争性干扰GPIb-vWF复合物的形成而非通过与游离瑞斯托霉素二聚体形成复合物来半特异性地抑制vWF结合。总之,瑞斯托霉素促进的vWF与其GPIb受体的结合是由电荷中和以及涉及GPIb和vWF A1结构域上天然相互作用位点附近脯氨酸残基的相互作用导致的。